At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Danicopandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Participants With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
In Brief
A Phase 2 clinical trial evaluating Danicopan for C3 Glomerulonephritis and 4 related conditions. Completed, enrolled 6 participants across 3 sites in 3 countries.
Detailed Summary
The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC3 Glomerulonephritis, Dense Deposit Disease, C3 Glomerulopathy, Immune Complex Mediated Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis Types I, II, and III
CountriesAustralia, Belgium, Netherlands
CollaboratorsAchillion, a wholly owned subsidiary of Alexion
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartAug 2017
Primary CompletionDec 2018
Study CompletionJan 2019
TodayJul 2026
First PostedApr 21, 2017
Enrollment StartAug 9, 2017
Primary CompletionDec 21, 2018
Study CompletionJan 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.2 years ago
Interventions
Danicopandrug
Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).